Inventor · disambiguated record
Matthew G. Bursavich
Also filed as: BURSAVICH MATTHEW G · BURSAVICH MATTHEW GREGORY
25 granted patents·22 pending applications·96 citations·filing 2002–2024
95Inventor score
Files withMORPHIC THERAPEUTIC INC19WYETH CORP9FORUM PHARMACEUTICALS INC4DENALI THERAPEUTICS INC2IRONWOOD PHARMACEUTICALS INC2
Top patents by PatentIndex Score
47 records- 0196US12145935B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Nov 19, 2024·4 cites·20 claims
- 0296US11795167B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Oct 24, 2023·5 cites·19 claims
- 0395US11827621B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Nov 28, 2023·5 cites·9 claims
- 0495US11021480B2Inhibiting (α-V)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2020·Granted Jun 1, 2021·8 cites·2 claims
- 0594US12415796B2Inhibitors of (αv)(β6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Sep 16, 2025·2 cites·8 claims
- 0694US11739087B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Aug 29, 2023·5 cites·9 claims
- 0794US11046669B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Granted Jun 29, 2021·8 cites·35 claims
- 0893US11046685B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 29, 2021·8 cites·42 claims
- 0993US11040955B2Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 22, 2021·8 cites·59 claims
- 1093US10759756B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2019·Granted Sep 1, 2020·7 cites·42 claims
- 1191US9725453B2Imidazotriazinone compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2014·Granted Aug 8, 2017·7 cites·2 claims
- 1289US11370773B1Inhibiting human integrin (alpha-4) (beta-7)MORPHIC THERAPEUTIC INC·Filed 2021·Granted Jun 28, 2022·2 cites·24 claims
- 1387US7947712B28-hydroxyquinoline compounds and methods thereofWYETH LLC·Filed 2007·Granted May 24, 2011·9 cites·52 claims
- 1485US12459942B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Granted Nov 4, 2025·0 cites·18 claims
- 1585US12221416B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2023·Granted Feb 11, 2025·0 cites·20 claims
- 1685US6947847B2Method to design therapeutically important compoundsWISCONSIN ALUMNI RES FOUND·Filed 2002·Granted Sep 20, 2005·12 cites·13 claims
- 1784US2025223289A1Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 1883US11174228B2Antagonists of human integrin (α4)(β7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Nov 16, 2021·1 cites·20 claims
- 1981US11104661B1Inhibiting human integrin (α-4) (β-7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Aug 31, 2021·1 cites·24 claims
- 2080US7799915B2Anilino-pyrimidine analogsWYETH LLC·Filed 2005·Granted Sep 21, 2010·4 cites·59 claims
- 2172US2022340529A1Antagonists of human integrin (alpha4)(beta7)MORPHIC THERAPEUTIC INC·Filed 2021·Application pending·0 cites
- 2268US2020071322A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Application pending·0 cites
- 2367US2020354359A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2020·Application pending·0 cites
- 2455US2009325964A1Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/DepressionWYETH CORP·Filed 2009·Application pending·0 cites
- 2553US9969742B2Imidazotriazinone compoundsIRONWOOD PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·0 cites·3 claims
- 2653US2010015141A14-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesesWYETH CORP·Filed 2009·Application pending·0 cites
- 2752US2009048282A1Pyrimidine sulfonamide analogs and their use as agonists of the wnt-beta-catenin cellular messaging systemWYETH CORP·Filed 2008·Application pending·0 cites
- 2851US2008287452A1Heteroaryl/aryl pyrimidine analogs and their use as agonists of the wnt-beta-catenin cellular messaging systemWYETH CORP·Filed 2008·Application pending·0 cites
- 2949US2015352108A1Amino-pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilonALZHEIMER S INST OF AMERICA·Filed 2014·Application pending·0 cites
- 3048US2009298820A13-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesesWYETH CORP·Filed 2009·Application pending·0 cites
- 3148US2009311217A13-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesesWYETH CORP·Filed 2009·Application pending·0 cites
- 3248US2008234262A1Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitorsWYETH CORP·Filed 2008·Application pending·0 cites
- 3347US2008233127A1Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitorsWYETH CORP·Filed 2008·Application pending·0 cites
- 3444US9802927B2Oxadiazine compounds and methods of use thereofDENALI THERAPEUTICS INC·Filed 2016·Granted Oct 31, 2017·0 cites·19 claims
- 3544US2012238540A1Amino-pyrimidine compounds as inhibitors of ikk epsilon and/or tbk1HOLCOMB RYAN C·Filed 2012·Application pending·0 cites
- 3643US9771378B2Fused morpholinopyrimidines and methods of use thereofDENALI THERAPEUTICS INC·Filed 2016·Granted Sep 26, 2017·0 cites·20 claims
- 3742US2012329786A1Compounds and therapeutic uses thereofWILLARDSEN J ADAM·Filed 2012·Application pending·0 cites
- 3841US2008125469A1Thiadiazole compounds and methods of use thereofWYETH CORP·Filed 2007·Application pending·0 cites
- 3939US10370370B2Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptorsFORUM PHARMACEUTICALS INC·Filed 2016·Granted Aug 6, 2019·0 cites·13 claims
- 4038US10428062B2Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptorsFORUM PHARMACEUTICALS INC·Filed 2016·Granted Oct 1, 2019·0 cites·13 claims
- 4138US2013317027A1Compounds and therapeutic uses thereofMYREXIS INC·Filed 2012·Application pending·0 cites
- 4238US2017050980A1Oxadiazine compounds and methods of use thereofFORUM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4337US2017247393A1Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine ReceptorsFORUM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4436US2014288044A1Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitorsHOLCOMB RYAN·Filed 2012·Application pending·0 cites
- 4535US10183938B2Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptorsAXOVANT SCIENCES GMBH·Filed 2015·Granted Jan 22, 2019·0 cites·15 claims
- 4634US2012122840A1Compounds and therapeutic uses thereofKUMAR DANGE VIJAY·Filed 2011·Application pending·0 cites
- 4734US2015353538A1Compounds and therapeutic uses thereofWILLARDSEN J ADAM·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →